Global Transdermal Drug Delivery Market Trends and Drivers, Restraints, and Opportunities 2017-2023

Global Transdermal Drug Delivery Market Trends and Drivers, Restraints, and Opportunities 2017-2023

  • Report Code ID: RB90557
  • Category Healthcare
  • No. of Pages 85
  • Publication On Nov 2017
  • Publisher Name Infoholic Research
Transdermal Drug Delivery Market - Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017-2023
Overview: Transdermal drug delivery system (TDDS) is an independent, distinct dosage form of drug applied to intact skin to deliver the drug at a meticulous rate to the blood. The transdermal route of governing the drugs is known to be one of the budding route for indigenous and systemic drug delivery process.
The first transdermal drug delivery system, Transderm-SCOP received US FDA approval in the year 1979 for the stoppage of nausea and vomiting. Since then the technology has greatly developed. The first-generation transdermal drug delivery majorly involved delivery of small, lipophilic, and uncharged molecules by passive diffusion technology. Maximum products that are currently available in the market belong to this generation. However, development of technology has led to the use of chemical enhancers and other energy-based techniques such as ultrasound to enhance the permeation of the drug through the skin. They belong to the second generation of transdermal products. The delivery of lidocaine is done by an iontophoretic delivery system, which was developed and marketed during this generation. A third generation of delivery systems are the ones that are currently under development including microneedles and electroporation to deliver macromolecules.
Market Analysis: The Global Transdermal Drug Delivery Market is estimated to witness a CAGR of 9.5% during the forecast period 2017-2023. The Transdermal Drug Delivery market is analyzed based on four segments - Product Type, Technology, Drug Type, and Regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). In the North American region, the US is set to be the leading country. The Europe is set to be the second leading region and holds more than 26.3% of the market share in 2016. In Asia Pacific, India, Japan, and China is one of the most attractive countries for the players and holds huge business opportunities. RoW is set to be an emerging market in the next 5-6 years.
Technology Analysis: Based on the technology types, the market is segmented into Passive and Active transdermal technology. At present the market is dominated by passive technology. However, the advent of novel technology for enhancing the permeation of drugs through skin the skin is driving the market growth. Hence the highest growth rate is expected to be in witnessed in the active transdermal drug delivery technology.
Product Types Analysis: The product types covered in the report are Patches and Gels. Transdermal Patches are likely to continue to dominate the market by 2023. Stringent regulatory approval and high cost of the transdermal drug delivery systems represents as the major challenge the growth of transdermal drug delivery market. The market is expected to be on a positive year on year growth rate, as the increase in chronic diseases prevalence and expanded application areas of the technology is expected during the forecast period.
Key Players: 3M, Boehringer Ingelheim, Johnson and Johnson, Mylan N.V., Novartis, and GlaxoSmithKline, are the key players in the market. Echo Therapeutics Inc., Noven Pharmaceuticals, Transdermal Corp, Actavis, Bayer, and Corium International, are the other key players in the market.
Competitive Analysis: The transdermal drug delivery market is highly lucrative. Many players are developing advanced technology products and if involved in expanding the application areas of these drug delivery systems. In 2017, Nemaura Pharma, a UK-based company has developed Memspatch, to increase the penetration rate of gel by three-times faster than the ones that are already available in the market. Apart from this the major players in the market are collaborating with other major players in the market. For instance, In January 2017, 3M Drug Delivery Systems entered into collaboration with Panacea Pharmaceuticals, Inc. to deliver a new therapeutic cancer vaccine directly to the dermis through the 3M Hollow Microstructure Transdermal System (hMTS).
Benefits: The report provides complete details about the usage and adoption rate of transdermal drug delivery in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical players initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:

Companies Mentioned

3M, Boehringer Ingelheim, Johnson and Johnson, Mylan N.V., Novartis, and GlaxoSmithKline, are the key players in the market. Echo Therapeutics Inc., Noven Pharmaceuticals, Transdermal Corp, Actavis, Bayer, and Corium International, are the other key players in the market
Table of Contents
1 Industry Outlook 9
1.1 Industry Overview 9
1.2 Industry Trends 9
1.3 Total Addressable Market 10
2 Report Outline 11
2.1 Report Scope 11
2.2 Report Summary 11
2.3 Research Methodology 12
2.4 Report Assumptions 13
3 Market Snapshot 13
3.1 Market Definition - Infoholic Research 14
3.2 Segmented Addressable Market 14
3.2.1 Components of Transdermal Patch 15
3.2.2 Advantages of Transdermal Drug Delivery 15
3.2.3 Disadvantages of Transdermal Drug Delivery 15
3.2.4 Diseases Treated by Transdermal Drug Delivery Systems 15
3.2.5 Trends in Transdermal Drug Delivery Market 16
3.3 Related Markets 17
3.3.1 Active Pharmaceutical Ingredients 17
3.3.2 Pulmonary Drug Delivery Systems 18
3.3.3 Injectable Drug Delivery Systems 18
4 Market Outlook 19
4.1 Overview 19
4.2 Market Segmentation 20
4.3 Porter 5(Five) Forces 20
4.4 PEST Analysis 21
5 Market Characteristics 22
5.1 Market Dynamics 22
5.1.1 Drivers 23
5.1.1.1 Increasing aging population 23
5.1.1.2 Growing patient base of chronic diseases 23
5.1.1.3 Increasing demand for transdermal drug delivery 24
5.1.2 Opportunities 24
5.1.2.1 Increased healthcare spending 24
5.1.2.2 Increasing clinical trials and product launches 24
5.1.3 Restraints 25
5.1.3.1 Side effects of transdermal drug delivery 25
5.1.3.2 Delivery limitation through skin 25
5.1.3.3 Availability of alternative drug delivery systems 26
5.2 DRO - Impact Analysis 26
5.3 Key Stakeholders 26
6 Types: Market Size and Analysis 27
6.1 Overview 27
6.2 Patches 28
6.3 Gels 29
7 Technology: Market Size and Analysis 29
7.1 Overview 30
7.2 Passive 30
7.3 Active 30
7.3.1 Thermal Technology 31
7.3.2 Ultrasound Devices 31
7.3.3 Electrical Techniques 31
7.3.4 Mechanical Methods 32
7.3.5 Velocity-based Devices 33
8 Drug Types: Market Size and Analysis 33
8.1 Overview 33
8.2 Fentanyl 33
8.3 Nicotine Transdermal Patch 34
8.4 Nitroglycerin Transdermal Patch 34
8.5 Clonidine Transdermal Patch 34
8.6 Estradiol 35
8.7 Testosterone 35
8.8 Others 35
9 Regions: Market Size and Analysis 35
9.1 Overview 35
9.2 North America 36
9.2.1 Overview 36
9.3 Europe 38
9.3.1 Overview 38
9.4 Asia Pacific 39
9.4.1 Overview 39
9.5 Rest of the World 40
9.5.1 Overview 40
10 Competitive Landscape 41
11 Vendor Profiles 44
11.1 Novartis AG 44
11.1.1 Overview 44
11.1.2 Business Units 47
11.1.3 Geographic Revenue 48
11.1.4 Business Focus 49
11.1.5 SWOT Analysis 49
11.1.6 Business Strategies 50
11.2 3M 51
11.2.1 Overview 51
11.2.2 Business Units 52
11.2.3 Geographic Revenue 53
11.2.4 Business Focus 54
11.2.5 SWOT Analysis 55
11.2.6 Business Strategies 55
11.3 Johnson & Johnson (Janssen Pharmaceuticals Inc.) 55
11.3.1 Overview 55
11.3.2 Business Units 59
11.3.3 Geographic Revenue 60
11.3.4 Business Focus 61
11.3.5 SWOT Analysis 62
11.3.6 Business Strategies 63
11.4 GlaxoSmithKline plc 63
11.4.1 Overview 63
11.4.2 Business Units 65
11.4.3 Geographic Revenue 66
11.4.4 Business Focus 67
11.4.5 SWOT Analysis 67
11.4.6 Business Strategies 68
11.5 Boehringer Ingelheim GmbH 68
11.5.1 Overview 68
11.5.2 Business Units 70
11.5.3 Geographic Revenue 71
11.5.4 Business Focus 72
11.5.5 SWOT Analysis 72
11.5.6 Business Strategies 73
11.6 Mylan N.V. 73
11.6.1 Overview 73
11.6.2 Business Units 75
11.6.3 Geographic Revenue 77
11.6.4 Business Focus 77
11.6.5 SWOT Analysis 77
11.6.6 Business Strategies 78
12 Companies to Watch For 78
12.1 Echo Therapeutics, Inc. 78
12.1.1 Overview 78
12.1.2 Highlights 79
12.2 Noven Pharmaceuticals, Inc. 79
12.2.1 Overview 79
12.2.2 Highlights 80
12.3 Transdermal Corp. 80
12.3.1 Overview 80
12.4 Bayer AG 81
12.4.1 Overview 81
12.5 Actavis, Inc. 82
12.5.1 Overview 82
12.6 Corium International, Inc. 82
12.6.1 Overview 82
Annexure 84
Abbreviations 84

?

List of Figures

Charts
CHART 1 RESEARCH METHODOLOGY OF GLOBAL TRANSDERMAL DRUG DELIVERY MARKET 13
CHART 2 GLOBAL TRANSDERMAL DRUG DELIVERY MARKET REVENUE, 2016-2023 ($MILLION) 18
CHART 3 SEGMENTATION OF GLOBAL TRANSDERMAL DRUG DELIVERY MARKET 21
CHART 4 PORTER 5 FORCES OF TRANSDERMAL DRUG DELIVERY MARKET 21
CHART 5 PEST ANALYSIS OF TRANSDERMAL DRUG DELIVERY MARKET 22
CHART 6 MARKET DYNAMICS - DRO ANALYSIS 23
CHART 7 DRO - IMPACT ANALYSIS OF GLOBAL TRANSDERMAL DRUG DELIVERY MARKET 27
CHART 8 KEY STAKEHOLDERS 27
CHART 9 TRANSDERMAL DRUG DELIVERY MARKET SHARE BY TYPES SEGMENTATION, 2016 VS 2023 (%) 28
CHART 10 TRANSDERMAL DRUG DELIVERY PATCHES MARKET REVENUE BY TYPES SEGMENTATION, 2016-2023 ($MILLION) 29
CHART 11 TRANSDERMAL DRUG DELIVERY GELS MARKET REVENUE BY TYPES SEGMENTATION, 2016-2023 ($MILLION) 30
CHART 12 TRANSDERMAL DRUG DELIVERY MARKET SHARE BY TECHNOLOGY SEGMENTATION, 2016 (%) 31
CHART 13 TRANSDERMAL DRUG DELIVERY MARKET SHARE BY DRUG TYPE, 2016 (%) 34
CHART 14 TRANSDERMAL DRUG DELIVERY MARKET SHARE BY REGIONAL SEGMENTATION, 2016 VS 2023 (%) 36
CHART 15 TRANSDERMAL DRUG DELIVERY MARKET REVENUE IN NORTH AMERICA, 2016-2023 ($MILLION) 38
CHART 16 TRANSDERMAL DRUG DELIVERY MARKET REVENUE IN EUROPE, 2016-2023 ($MILLION) 39
CHART 17 TRANSDERMAL DRUG DELIVERY MARKET REVENUE IN ASIA PACIFIC, 2016-2023 ($MILLION) 41
CHART 18 TRANSDERMAL DRUG DELIVERY MARKET REVENUE IN REST OF THE WORLD, 2016-2023 ($MILLION) 42
CHART 19 NOVARTIS AG: OVERVIEW SNAPSHOT 47
CHART 20 NOVARTIS AG: BUSINESS UNITS 48
CHART 21 NOVARTIS AG: GEOGRAPHIC REVENUE 49
CHART 22 NOVARTIS AG: SWOT ANALYSIS 50
CHART 23 3M: OVERVIEW SNAPSHOT 52
CHART 24 3M: BUSINESS UNITS 53
CHART 25 3M: GEOGRAPHIC REVENUE 54
CHART 26 3M: SWOT ANALYSIS 56
CHART 27 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 59
CHART 28 JOHNSON & JOHNSON: BUSINESS UNITS 60
CHART 29 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 61
CHART 30 JOHNSON & JOHNSON: SWOT ANALYSIS 63
CHART 31 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT 66
CHART 32 GLAXOSMITHKLINE PLC: BUSINESS UNITS 66
CHART 33 GLAXOSMITHKLINE PLC: GEOGRAPHIC REVENUE 67
CHART 34 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 68
CHART 35 BOEHRINGER INGELHEIM GMBH: OVERVIEW SNAPSHOT 70
CHART 36 BOEHRINGER INGELHEIM GMBH: BUSINESS UNITS 71
CHART 37 BOEHRINGER INGELHEIM GMBH: GEOGRAPHIC REVENUE 72
CHART 38 BOEHRINGER INGELHEIM GMBH: SWOT ANALYSIS 73
CHART 39 MYLAN N.V. OVERVIEW SNAPSHOT 75
CHART 40 MYLAN N.V.: BUSINESS SEGMENTS 76
CHART 41 MYLAN N.V.: GEOGRAPHIC REVENUE 78
CHART 42 MYLAN N.V.: SWOT ANALYSIS 78

List of Tables

Tables

TABLE 1 TRANSDERMAL DRUG DELIVERY MARKET REVENUE BY REGIONS, 2016-2023 ($MILLION) 36
TABLE 2 PROMINENT VENDORS IN THE MARKET 42
TABLE 3 NOVARTIS AG: OFFERINGS 45
TABLE 4 NOVARTIS AG: RECENT DEVELOPMENTS 45
TABLE 5 3M: OFFERINGS 51
TABLE 6 3M: RECENT DEVELOPMENTS 51
TABLE 7 JOHNSON & JOHNSON: PRODUCT OFFERINGS 56
TABLE 8 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 56
TABLE 9 GLAXOSMITHKLINE PLC: OFFERINGS 63
TABLE 10 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 64
TABLE 11 BOEHRINGER INGELHEIM GMBH: OFFERINGS 69
TABLE 12 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS 69
TABLE 13 MYLAN N.V.: OFFERINGS 74
TABLE 14 MYLAN N.V.: RECENT DEVELOPMENTS 74
TABLE 15 ECHO THERAPEUTICS, INC.: OVERVIEW 79
TABLE 16 NOVEN PHARMACEUTICALS, INC.: OVERVIEW 79
TABLE 17 TRANSDERMAL CORP.: OVERVIEW 80
TABLE 18 BAYER AG: OVERVIEW 81
TABLE 19 BAYER AG: RECENT DEVELOPMENTS 81
TABLE 20 ACTAVIS, INC.: OVERVIEW 82
TABLE 21 CORIUM INTERNATIONAL, INC.: OVERVIEW 82
TABLE 22 CORIUM INTERNATIONAL, INC.: RECENT DEVELOPMENTS 83

?

Related Products